Navigation Links
PDL BioPharma Provides $70 Million in Financing to Durata Therapeutics
Date:11/6/2013

lnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.

About PDL BioPharma, Inc.

PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue. PDL is currently focused on intellectual property asset management, investing in new income generating assets, and maximizing value for its shareholders.

The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada.

In 2011, PDL initiated a strategy to bring in new income generating assets from the healthcare sector. To accomplish this goal, PDL seeks to provide non-dilutive growth capital and financing solutions to late stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL successfully executed on this strategy by deploying over $125 million in 2012 and continues to pursue this strategic initiative. PDL is focused on the quality of the income generating assets and potential returns on investment.  

For more information, please visit www.pdl.com.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015   Prime Therapeutics LLC (Prime), a ... members, today released the following statement responding to the ... first biosimilar to enter the U.S. market. ... of Sandoz,s Zarxio® to treat neutropenia, a condition affecting ... milestone in our country,s journey to curb the escalating ...
(Date:3/6/2015)... Solutions, Inc. (Pink Sheets: ASDS ) ("Ascendant" ... fourth quarter and year ended December 31, 2014. The ... than $0.01 per share, on revenues of $8,018,000 for ... net income of $195,000, or $0.01 per share, on ... The substantial increase in fourth quarter 2014 revenue was ...
(Date:3/6/2015)... TAMPA, Fla. , March 6, 2015 /PRNewswire/ ... received special validation from Intuitive Surgical, the manufacturer ... for their Triton-36 Instrument Cleaning System. This approval ... highest standards in cleanliness currently in place for ... this special validation for reprocessing robotic surgical instruments ...
Breaking Medicine Technology:Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 2Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 2Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 4Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 5Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2
... Inc. (Nasdaq: ENZN) announced today that four,posters containing ... Meeting of the American Association for Cancer Research,(AACR) ... 2007 in Los Angeles, CA., Details of the ... EZN-2208, a novel polyethyleneglycol-SN38,conjugate, has potent antitumor activity ...
... 13, 2007 - Point Therapeutics, Inc.,(NASDAQ: POTP) today ... 2007 Annual Meeting of the American,Association for Cancer ... 14-18, 2007. The AACR poster presentations report,on preclinical ... details for the AACR presentations are as,follows: , ...
Cached Medicine Technology:Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting 2
(Date:3/6/2015)... 06, 2015 Follow us on ... most common forms of cancer and is the leading ... be screened through various techniques and tools, including mammography, ... the gold standard technique in breast cancer screening, driven ... taken for the procedure, required expertise to carry out ...
(Date:3/6/2015)... “On Tap” takes the audience on a journey ... the silver screen and to modern day rhythm tap. ... their famous eye-high kicks! Producers, directors and choreographers Mary Six ... dancing in this robust show, showcasing one of the only ... , “On Tap” is proud to host guest stars ...
(Date:3/6/2015)... 2015 As the Association of ... of 90,000 doctors by 2025 is updated this week ... (SH) is proactively preparing by analyzing demographics and pursuing ... , Several factors including the increasing number of ... under the Affordable Care Act and an uneven distribution ...
(Date:3/6/2015)... 2015 Jvion, the Atlanta-based leader ... a Clostridium Difficile (C Diff) predictive use case ... use case is the latest in a broad ... infections, chronic conditions, and individual illnesses. Using the ... solution flags at risk individuals to help support ...
(Date:3/6/2015)... Yisrayl Hawkins, Pastor and Overseer of ... a new publication explaining how micro-kingdoms keep the earth ... article titled “Microorganisms Do Much More Than You Think” ... were created and designed to keep all things functioning ... the functions of these micro-kingdom, but does not realize ...
Breaking Medicine News(10 mins):Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 3Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 4Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2
... which is angered by the defence attorneys of the AIIMS ... about the case where a boy, suffering from cancer, got ... 2001. ,The victim, who was nine years ... in July 2000 for treatment of cancer, supposedly has contracted ...
... the Human Fertilization and Embryology Authority show that recently ... opting for assisted reproduction technology// (ART) in the UK. ... of these women is 34. There is increase in ... for infertility. The doctors and scientists say that there ...
... new study, the antidepressant drug Zoloft (sertraline) may avoid ... also increase// the time interval between the depressive episodes. ... to background information in the study, reports foodconsumer.org. ... of age, who had recovered from depression during treatment ...
... the UK have been busy. They have tolled up 100,000 ... stop and control the spread of bird flu.// Researchers eleven ... they screened possible drug components that could be effective against ... the UK was originally built to help particle physicists examine ...
... A recent conducted at University of Michigan Health Systems ... have greater expectations of doom from their screening //mammography ... than not these expectations were unusually high or unrealistic. ... to an outpatient clinic for screening mammography. The participants ...
... the oldest mother in UK, from Lewes in East Sussex, ... fertility treatment. She gave the statement that this child had ... John Farrant made a joint statement, "We wish to emphasise ... without courage. A great deal of thought has been given ...
Cached Medicine News:Health News:A Boy Undergoing Treatment For Cancer Gets AIDS At AIIMS 2Health News:UK Computer Grid In Bird Flu Fight 2Health News:UK Computer Grid In Bird Flu Fight 3Health News:Most Women Have Unrealistic Expectations From Screening Mammography 2Health News:A mother at 63: oldest in UK! 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: